- Home
- LOKV vs SIGA Comparison
LOKV vs SIGA Comparison
Compare LOKV & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$4.58
Company Overview
Basic Information| Metric | LOKV | SIGA |
|---|---|---|
| Founded | 2024 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.4M | 341.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | LOKV | SIGA |
|---|---|---|
| Price | $10.45 | $4.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.7K | ★ 729.5K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $224.81 |
| P/E Ratio | ★ N/A | $14.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $4.29 |
| 52 Week High | $11.46 | $9.62 |
Technical Indicators
Market Signals| Indicator | LOKV | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 64.97 | 40.35 |
| Support Level | $10.24 | $4.29 |
| Resistance Level | $10.49 | $4.80 |
| Average True Range (ATR) | 0.02 | 0.16 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 66.67 | 55.88 |
Price Performance
Historical Comparison LOKV
SIGA
About LOKV Live Oak Acquisition Corp. V Class A Ordinary Shares
Live Oak Acquisition Corp V is a blank check company.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.